Crossmark

Increases in inflammatory and CD14dim/CD16pos/CD45pos patrolling monocytes in sepsis: correlation with final outcome

Crossref DOI link: https://doi.org/10.1186/s13054-018-1977-1

Published Online: 2018-03-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gainaru, Gabriela

Papadopoulos, Antonios

Tsangaris, Iraklis

Lada, Malvina

Giamarellos-Bourboulis, Evangelos J. http://orcid.org/0000-0003-4713-3911
Pistiki, Aikaterini
Funding

Funding for this research was provided by:

Hellenic Institute for the Study of Sepsis
More Information

Article History

Received: 23 June 2017

Accepted: 5 February 2018

First Online: 3 March 2018

Ethics approval and consent to participate

: This study constitutes a substudy of a large prospective randomized clinical trial (registration NCT012236690). The study was approved by the ethics committee of “ATTIKON” University Hospital (266/27-07-9). Patients were enrolled after written informed consent provided by themselves or by their legal representative for patients unable to consent.

: Patients or legal representatives consented to the publication of clinical data.

: EJGB has received honoraria for providing scientific advice to AbbVie (Chicago IL, USA), Astellas (Athens, Greece), Biotest AG (Dreieich, Germany), and ThermoFisher Scientific GmbH (Henningdorf, Germany). He has received unrestricted educational funding from Biotest AG, ThermoFisher Scientific GmbH, Sanofi SA, (Athens, Greece), the Seventh Framework European Program HemoSpec, and the Horizon 2020 Marie-Curie grant European Sepsis Academy. The remaining authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below